[1]
|
Paik, J.M., Golabi, P., Younossi, Y., Mishra, A. and Younossi, Z.M. (2020) Changes in the Global Burden of Chronic Liver Diseases from 2012 to 2017: The Growing Impact of NAFLD. Hepatology, 72, 1605-1616.
https://doi.org/10.1002/hep.31173
|
[2]
|
Powell, E.E., Wong, V.W.S. and Rinella, M. (2021) Non-Alcoholic Fatty Liver Disease. The Lancet, 397, 2212-2224.
https://doi.org/10.1016/S0140-6736(20)32511-3
|
[3]
|
Estes, C., Anstee, Q.M., Arias-Loste, M.T., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. https://doi.org/10.1016/j.jhep.2018.05.036
|
[4]
|
Bianco, C., Jamialahmadi, O., Pelusi, S., et al. (2021) Non-Invasive Stratification of Hepatocellular Carcinoma Risk in Non-Alcoholic Fatty Liver Using Polygenic Risk Scores. Journal of Hepatology, 74, 775-782.
https://doi.org/10.1016/j.jhep.2020.11.024
|
[5]
|
Luukkonen, P.K., Qadri, S., Ahlholm, N., et al. (2021) Distinct Contributions of Metabolic Dysfunction and Genetic Risk Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. The Journal of Hepatology, 76, 526-535.
|
[6]
|
De Vincentis, A., Tavaglione, F., Jamialahmadi, O., et al. (2022) A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clinical Gastroenterology and Hepatology, 20, 658-673. https://doi.org/10.1016/j.cgh.2021.05.056
|
[7]
|
Trepo, E. and Valenti, L. (2020) Update on NAFLD Genetics: From New Variants to the Clinic. Journal of Hepatology, 72, 1196-1209. https://doi.org/10.1016/j.jhep.2020.02.020
|
[8]
|
Ciesielska, A., Matyjek, M. and Kwiatkowska, K. (2021) TLR4 and CD14 Trafficking and Its Influence on LPS-Induced Pro-Inflammatory Signaling. Cellular and Molec-ular Life Sciences, 78, 1233-1261.
https://doi.org/10.1007/s00018-020-03656-y
|
[9]
|
Plociennikowska, A., Hromada-Judycka, A., Borzecka, K. and Kwiatkowska, K. (2015) Co-Operation of TLR4 and Raft Proteins in LPS-Induced Pro-Inflammatory Signaling. Cellular and Molecular Life Sciences, 72, 557-581.
https://doi.org/10.1007/s00018-014-1762-5
|
[10]
|
Gao, H.H., Li, W., Shou, X.Y. and Mao, J.-H. (2023) Correlation between Toll-Like Receptor Gene Polymorphisms and Idiopathic Nephrotic Syndrome in Chinese Children. Current Medical Science, 43, 585-591.
https://doi.org/10.1007/s11596-023-2728-3
|
[11]
|
Li, T., Jing, J.J., Dong, N.N., Liu, X. and Ma, C. (2021) TLR4 rs1927914 Polymorphism Contributes to Serum TLR4 Levels in Patients with Aortic Aneurysm. Experimental and Mo-lecular Pathology, 119, Article ID: 104609.
https://doi.org/10.1016/j.yexmp.2021.104609
|
[12]
|
Xu, Y.X., Jiang, Z.X., Huang, J.H., Meng, Q., Coh, P. and Tao, L. (2015) The Association between Toll-Like Receptor 4 Polymorphisms and Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes. British Journal of Ophthalmology, 99, 1301-1305. https://doi.org/10.1136/bjophthalmol-2015-306677
|
[13]
|
Drozdz, K., Nabrdalik, K., Hajzler, W., et al. (2022) Met-abolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients, 14, Article 103.
https://doi.org/10.3390/nu14010103
|
[14]
|
Cohen, J.C., Horton, J.D. and Hobbs, H.H. (2011) Human Fatty Liver Disease: Old Questions and New Insights. Science, 332, 1519-1523. https://doi.org/10.1126/science.1204265
|
[15]
|
Heeren, J. and Scheja, L. (2021) Metabolic-Associated Fatty Liver Disease and Lipoprotein Metabolism. Molecular Metabolism, 50, Article ID: 101238. https://doi.org/10.1016/j.molmet.2021.101238
|
[16]
|
Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Mul-tiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism-Clinical and Experimental, 65, 1038-1048.
https://doi.org/10.1016/j.metabol.2015.12.012
|
[17]
|
Li, T., Jing, J.J., Sun, L.P., et al. (2019) TLR4 and MMP2 Polymorphisms and Their Associations with Cardiovascular Risk Factors in Susceptibility to Aortic Aneurysmal Dis-eases. Bioscience Reports, 39, BSR20181591..
https://doi.org/10.1042/BSR20181591
|
[18]
|
Singh, K., Singh, V.K., Agrawal, N.K., Gupta, S.K. and Singh, K. (2013) Association of Toll-Like Receptor 4 Polymorphisms with Diabetic Foot Ulcers and Application of Artificial Neu-ral Network in DFU Risk Assessment in Type 2 Diabetes Patients. BioMed Research International, 2013, Article ID: 318686. https://doi.org/10.1155/2013/318686
|
[19]
|
Zhang, H.M., Gao, H., Li, A., et al. (2022) TLR4 Regulatory Region Variants Reduce the Susceptibility of Small-Cell Lung Cancer in Chinese Population. European Journal of Can-cer Prevention, 31, 363-368.
https://doi.org/10.1097/CEJ.0000000000000737
|
[20]
|
Li, J.Y., Wu, H.J., Gao, H., et al. (2021) TLR4 Promoter rs1927914 Variant Contributes to the Susceptibility of Esophageal Squamous Cell Carcinoma in the Chinese Population. PeerJ, 9, e10754. https://doi.org/10.7717/peerj.10754
|
[21]
|
Shi, G., Wang, T.T., Li, S.J., et al. (2016) TLR2 and TLR4 Polymorphisms in Southern Chinese Psoriasis Vulgaris patients. Journal of Dermatological Science, 83, 145-147. https://doi.org/10.1016/j.jdermsci.2016.04.014
|
[22]
|
Gu, L., Huang, J.Y., Liang, B.Y., et al. (2018) TLR4 Poly-morphisms Affect Stroke Risk and Inflammatory Response in Chinese Ischemic Stroke Patients. Neurological Sciences, 39, 127-133. https://doi.org/10.1007/s10072-017-3151-y
|
[23]
|
Chen, R.X., Dai, M.D., Zhang, Q.Z., Lu, M.P., Wang, M.L., Yin, M., Zhu, X.J., Wu, Z.F., Zhang, Z.D. and Cheng, L. (2022) TLR Signaling Pathway Gene Polymor-phisms, Gene-Gene and Gene-Environment Interactions in Allergic Rhinitis. Journal of Inflammation Research, 15, 3613-3630. https://doi.org/10.2147/JIR.S364877
|
[24]
|
Maciel-Fiuza, M.F., Costa, P.D.S., Kowalski, T.W., et al. (2022) Evaluation of Polymorphisms in Toll-Like Receptor Genes as Biomarkers of the Response to Treatment of Ery-thema Nodosum Leprosum. Frontiers in Medicine, 8, Article 713143. https://doi.org/10.3389/fmed.2021.713143
|
[25]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease- Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology, 64, 73-84.
https://doi.org/10.1002/hep.28431
|
[26]
|
Zhao, X.F., An, X.D., Yang, C.Q., et al. (2023) The Crucial Role and Mechanism of Insulin Resistance in Metabolic Disease. Frontiers in Endocrinology, 14, Article 1143239. https://doi.org/10.3389/fendo.2023.1149239
|
[27]
|
Shi, G.J., Wang, C.X., Zhang, P., Ji, L., Xu, S., Tan, X. and Li, H. (2017) Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carci-noma Recurrence Following Liver Transplantation. Archives of Medical Research, 48, 553-560. https://doi.org/10.1016/j.arcmed.2017.11.011
|
[28]
|
Shi, M.M., Xu, X.Q., Chen, H., et al. (2011) Single Nucleotide Polymorphisms of Toll-Like Receptor 4 Decrease the Risk of Development of Hepatocellular Carcinoma. PLOS ONE, 6, e19466.
https://doi.org/10.1371/journal.pone.0019466
|
[29]
|
Marchesini, G., Bugianesi, E., Forlani, G., et al. (2003) Nonal-coholic Fatty Liver, Steatohepatitis and the Metabolic Syndrome. Hepatology, 37, 917-923. https://doi.org/10.1053/jhep.2003.50161
|
[30]
|
Newberry. E.P., Hall, Z., Xie, Y., et al. (2021) Liver-Specific Dele-tion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. Hepatology, 74, 1203-1219. https://doi.org/10.1002/hep.31771
|
[31]
|
Kozlitina, J., Smagris, E., Stender, S., et al. (2014) Exome-Wide Associa-tion Study Identifies a TM6SF2 Variant that Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nature Genetics, 46, 352-356.
https://doi.org/10.1038/ng.2901
|
[32]
|
Loomba, R., Friedman, S.L. and Shulman, G.I. (2021) Mechanisms and Dis-ease Consequences of Nonalcoholic Fatty Liver Disease. Cell, 184, 2537-2564. https://doi.org/10.1016/j.cell.2021.04.015
|
[33]
|
Du, D.Y., Liu, C., Qin, M.Y., Zhang,X., Xi, T., Yuan, S., Hao, H. And Xiong, J. (2022) Metabolic Dysregulation and Emerging Therapeutical Targets for Hepatocellular Carcinoma. Acta Pharmaceutica Sinica B, 12, 558-580.
https://doi.org/10.1016/j.apsb.2021.09.019
|
[34]
|
Mcglynn, K.A., Petrick, J.L. and El-Serag, H.B. (2021) Epidemi-ology of Hepatocellular Carcinoma. Hepatology, 73, 4-13. https://doi.org/10.1002/hep.31288
|